Stocks of major drug makers and biotech companies plummeted as Donald Trump expressed interest in appointing vaccine skeptic Robert F. Kennedy Jr. as head of the U.S. Department of Health and Human Services. This decision sparked concerns within the industry and led to potential lobbying efforts against Kennedy's nomination.